- Published
- 01 June 2020
- Journal article
ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group
- Authors
-
- Source
- The Lancet Child & Adolescent Health
Abstract
The coronavirus disease 2019 (COVID-19) pandemic is creating unprecedented challenges at every level of society. Individuals with neurodevelopmental disorders, such as attention-deficit hyperactivity disorder (ADHD), are particularly vulnerable to the distress caused by the pandemic and physical distancing measures, and they might display increased behavioural problems. The crisis also poses several important questions for clinicians on how best to deliver care within the new restrictions. Therefore, the European ADHD Guidelines Group (EAGG) has developed guidance on the assessment and management of ADHD during the COVID-19 virus pandemic.
Rights
This content is not covered by the Open Government Licence. Please see source record or item for information on rights and permissions.
Cite as
Cortese, S., Asherson, P., Sonuga-Barke, E., Banaschewski, T., Brandeis, D., Buitelaar, J., Coghill, D., Daley, D., Danckaerts, M., Dittmann, R., Doepfner, M., Ferrin, M., Hollis, C., Holtmann, M., Konofal, E., Lecendreux, M., Santosh, P., Rothenberger, A., Soutullo, C., Steinhausen, H., Taylor, E., Van der Oord, S., Wong, I., Zuddas, A. & Simonoff, E. 2020, 'ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group', The Lancet Child & Adolescent Health, 4(6), pp. 412-414. https://doi.org/10.1016/S2352-4642(20)30110-3